Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wayne Foster

Facial Plastic Surgery Toms River, NJ Medical Doctor

NPI 1316052699 CMS profile 59800

500 Lakehurst Rd, Toms River, NJ 08755

Open in the dashboard

General payments

$2,485

41 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wayne Foster of Toms River, NJ is reported in the CMS Open Payments database as having received $2,485 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $176 7
2024 General $166 3
2023 General $31 2
2022 General $125 7
2021 General $27 2
2020 General $1,748 14
2019 General $212 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wayne Foster
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Wayne Foster were reported at $176. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Wayne Foster Facial Plastic Surgery median Middle half National median
2019 $212 $225 $92–$651 $163
2020 $1,748 $132 $45–$323 $114
2021 $27 $186 $67–$558 $132
2022 $125 $218 $83–$594 $149
2023 $31 $237 $94–$564 $160
2024 $166 $233 $104–$575 $164
2025 $176 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,924 16 payments
  2. AbbVie, Inc. $178 4 payments
  3. ConvaTec Inc. $142 6 payments
  4. Allergan Inc. $93 5 payments
  5. OptiNose US, Inc. $71 5 payments
  6. Organogenesis Inc. $19 1 payment
  7. AcelRx Pharmaceuticals, Inc. $16 1 payment
  8. Regeneron Healthcare Solutions, Inc. $15 1 payment
  9. GlaxoSmithKline, LLC. $13 1 payment
  10. Aerin Medical Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,464 38 payments
  2. Travel and Lodging $1,021 3 payments
Products named General payments · program years 2019–2025
  1. ENTELLUS - XPRESS ENT DILATION SYSTEM $1,828 10 payments
  2. ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM $374 4 payments
  3. SPIROX - LATERA $179 1 payment
  4. ENTELLUS - ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE $179 1 payment
  5. INNOVAMATRIX AC $142 6 payments
  6. Xhance $71 5 payments
  7. XPRESS LOPROFILE $33 1 payment
  8. DSUVIA $16 1 payment
  9. DUPIXENT $15 1 payment
  10. BOTOX $14 1 payment
  11. Other $79 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

575

Median for Otolaryngology: 297

Drug cost

$6,886

Median for Otolaryngology: $6,314

Branded share of claims

4.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 84 $2,867
Fluticasone Propionate Generic 132 $1,971
Cephalexin Generic 159 $756
Omeprazole Generic 31 $365
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $331
Levofloxacin Generic 24 $271
Azithromycin Generic 29 $138
Prednisone Generic 45 $113
Lorazepam Generic 46 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$1,010,500

Medicare's payments for the services billed

Medicare patients

1,632

Average age 76

Services billed

6,354

963 women, 669 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 41%
Diabetes 38%
Chronic kidney disease 25%
COPD 23%
Atrial fibrillation 21%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record